New Radiomedicine Technology

Chengdu New Radiomedicine Technology Co., Ltd. (NRT) is a biopharmaceutical company established in 2016, concentrating on the development and commercialization of radiopharmaceuticals. It was founded by Jiming Cai, Jihui Qian, and Maoliang Li, who are described as veterans in the nuclear medicine technology field. The company is headquartered in Chengdu, China, a significant hub for the nuclear industry, and has expanded its presence with four domestic subsidiaries and international offices in San Diego, USA, and Melbourne, Australia.

NRT's business model encompasses the entire value chain, from the production of medical isotopes to the innovation, research, and development of radiopharmaceutical drugs. The company serves the oncology market by providing hospitals and medical institutions with drugs for both the diagnosis and treatment of various cancers. Its revenue generation is supported by venture capital funding, with a Series C funding round in March 2024 raising over 300 million yuan ($41.8M USD) to advance its research and production capabilities. NRT also provides Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) services.

The company's core offering is a portfolio of radiopharmaceuticals, which are drugs containing radioactive elements used for medical imaging and therapy. A key area of focus is Radioligand Therapy (RLT), a targeted approach that delivers cytotoxic radiation directly to cancer cells by binding to specific biomarkers, thereby minimizing damage to healthy tissue. NRT's product pipeline includes TareSphere™, Yttrium-90 carbon microspheres for treating cancers with minimally invasive procedures, which are currently in late-stage clinical trials. It has also developed proprietary generator systems, the Galliator™ (Gallium-68) and Techneator™ (Technetium-99), and produces key medical isotopes like Lutetium-177. To support its production, NRT is installing a high-capacity Cyclone® IKON cyclotron, expected to be operational by 2025, which will produce a range of isotopes crucial for theranostics.

Keywords: radiopharmaceuticals, nuclear medicine, oncology, medical isotopes, theranostics, radioligand therapy, cancer treatment, CDMO, CMO, Yttrium-90, Gallium-68, Lutetium-177, clinical trials, biopharmaceutical, targeted therapy, cancer diagnosis, drug development, molecular imaging, nuclear technology, Chengdu